AR014054A1 - Una particula para trasnfectar celulas eucariotas superiores con moleculas de acidos nucleicos in vitro e in vivo, un metodo para su preparacion, unacomposicion farmaceutica que contiene una cantidad farmaceuticamente efectiva de dicha particula y un kit de piezas destinado a la preparacion, la - Google Patents
Una particula para trasnfectar celulas eucariotas superiores con moleculas de acidos nucleicos in vitro e in vivo, un metodo para su preparacion, unacomposicion farmaceutica que contiene una cantidad farmaceuticamente efectiva de dicha particula y un kit de piezas destinado a la preparacion, laInfo
- Publication number
- AR014054A1 AR014054A1 ARP980106157A ARP980106157A AR014054A1 AR 014054 A1 AR014054 A1 AR 014054A1 AR P980106157 A ARP980106157 A AR P980106157A AR P980106157 A ARP980106157 A AR P980106157A AR 014054 A1 AR014054 A1 AR 014054A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- molecules
- particle
- pharmaceutically effective
- acid molecules
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 10
- 150000007523 nucleic acids Chemical class 0.000 title abstract 10
- 102000039446 nucleic acids Human genes 0.000 title abstract 10
- 239000002245 particle Substances 0.000 title abstract 6
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000012682 cationic precursor Substances 0.000 abstract 4
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una partícula para transfectar células eucariotas superiores con moléculas de ácidos nucleicos in vitro e in vivo, que comprende una o más moléculas deácido nucleico condensadas por moléculas cationicas orgánicas, siendo obtenidas dichas partículas complejando las moléculas de ácido nucleico conmoléculas precursoras cationicas orgánicas idénticas o diferentes sin entrecruzar las moléculas de ácido nucleico, y uniendo covalentemente lasmoléculas precursoras entre sí sobre elmolde de ácido nucleico. Para la especificidad celular, la partícula puede llevar moléculas de especificidad osenalamiento como diana, por ejemplo azucares. Las moléculas precursoras cationicas preferidas son detergentes lipofilos que se unen para formar lípidosLa partícula contiene preferentemente solo una molécula de ácido nucleico, lo que hace util para la terapia génica y para el suministro de grande moléculasde ADN. Un método para preparar una partícula para transfeccion como la descripta más arriba, en el cual las moléculas precursoras cationicas seanaden a moléculas de ácido nucleico en un tampon adecuado se deja que formen complejos con el ácido nucleico y se deja que se unan covalentemente amoléculas precursoras cationicas idénticas o diferentes, sobre el molde de ácido nucleico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97121308A EP0945138A1 (en) | 1997-12-04 | 1997-12-04 | Transfection particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014054A1 true AR014054A1 (es) | 2001-01-31 |
Family
ID=8227738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106157A AR014054A1 (es) | 1997-12-04 | 1998-12-04 | Una particula para trasnfectar celulas eucariotas superiores con moleculas de acidos nucleicos in vitro e in vivo, un metodo para su preparacion, unacomposicion farmaceutica que contiene una cantidad farmaceuticamente efectiva de dicha particula y un kit de piezas destinado a la preparacion, la |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP0945138A1 (es) |
| JP (1) | JP2001525378A (es) |
| KR (1) | KR20010032775A (es) |
| CN (1) | CN1290178A (es) |
| AR (1) | AR014054A1 (es) |
| AU (1) | AU1757799A (es) |
| BR (1) | BR9814255A (es) |
| CA (1) | CA2312890A1 (es) |
| EE (1) | EE200000797A (es) |
| HU (1) | HUP0004322A3 (es) |
| IL (1) | IL136418A0 (es) |
| NO (1) | NO20002793L (es) |
| PL (1) | PL345849A1 (es) |
| SK (1) | SK8222000A3 (es) |
| TR (1) | TR200001597T2 (es) |
| UY (1) | UY25286A1 (es) |
| WO (1) | WO1999029349A1 (es) |
| ZA (1) | ZA9811011B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1289371A (zh) | 1998-01-30 | 2001-03-28 | 阿文蒂斯药物股份有限公司 | 对还原条件敏感的转染化合物,含有它们的药物组合物及其应用 |
| US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
| US10987308B2 (en) | 2014-09-03 | 2021-04-27 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods and systems |
| CN106496555B (zh) * | 2016-11-23 | 2019-02-01 | 南开大学 | 一种金属配位聚阳离子基因载体及其制备方法和应用 |
| US9963428B1 (en) * | 2017-03-20 | 2018-05-08 | Mark Quang Nguyen | Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use |
| BR112022002143A2 (pt) * | 2019-08-05 | 2022-04-19 | Polyplus Transfection | Composição adequada para transfectar uma molécula de ácido nucleico em uma célula, métodos para transfecção in vitro ou ex vivo de células vivas e para a produção e usos in vitro ou ex vivo da composição |
| CN114983942B (zh) * | 2022-05-18 | 2023-09-05 | 中国科学院理化技术研究所 | 治疗幽门螺杆菌感染的多功能微泡、制备及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873187A (en) * | 1986-03-13 | 1989-10-10 | Digene Diagnostics, Incorporated | Bifunctional DNA-protein conjugating agent |
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| WO1998010649A1 (en) * | 1996-09-13 | 1998-03-19 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
-
1997
- 1997-12-04 EP EP97121308A patent/EP0945138A1/en not_active Withdrawn
-
1998
- 1998-11-28 JP JP2000524018A patent/JP2001525378A/ja active Pending
- 1998-11-28 EE EEP200000797A patent/EE200000797A/xx unknown
- 1998-11-28 PL PL98345849A patent/PL345849A1/xx unknown
- 1998-11-28 BR BR9814255-0A patent/BR9814255A/pt not_active IP Right Cessation
- 1998-11-28 IL IL13641898A patent/IL136418A0/xx unknown
- 1998-11-28 KR KR1020007006071A patent/KR20010032775A/ko not_active Withdrawn
- 1998-11-28 EP EP98962400A patent/EP1037668A1/en not_active Withdrawn
- 1998-11-28 TR TR2000/01597T patent/TR200001597T2/xx unknown
- 1998-11-28 HU HU0004322A patent/HUP0004322A3/hu unknown
- 1998-11-28 CA CA002312890A patent/CA2312890A1/en not_active Abandoned
- 1998-11-28 WO PCT/EP1998/007695 patent/WO1999029349A1/en not_active Ceased
- 1998-11-28 AU AU17577/99A patent/AU1757799A/en not_active Abandoned
- 1998-11-28 CN CN98813498A patent/CN1290178A/zh active Pending
- 1998-11-28 SK SK822-2000A patent/SK8222000A3/sk unknown
- 1998-12-02 ZA ZA9811011A patent/ZA9811011B/xx unknown
- 1998-12-04 UY UY25286A patent/UY25286A1/es not_active Application Discontinuation
- 1998-12-04 AR ARP980106157A patent/AR014054A1/es not_active Application Discontinuation
-
2000
- 2000-05-31 NO NO20002793A patent/NO20002793L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010032775A (ko) | 2001-04-25 |
| TR200001597T2 (tr) | 2002-03-21 |
| HUP0004322A2 (hu) | 2001-02-28 |
| WO1999029349A1 (en) | 1999-06-17 |
| EE200000797A (et) | 2002-06-17 |
| EP0945138A1 (en) | 1999-09-29 |
| CA2312890A1 (en) | 1999-06-17 |
| SK8222000A3 (en) | 2000-12-11 |
| IL136418A0 (en) | 2001-06-14 |
| UY25286A1 (es) | 2001-01-31 |
| CN1290178A (zh) | 2001-04-04 |
| NO20002793L (no) | 2000-08-01 |
| HUP0004322A3 (en) | 2003-04-28 |
| ZA9811011B (en) | 1999-06-04 |
| PL345849A1 (en) | 2002-01-14 |
| JP2001525378A (ja) | 2001-12-11 |
| BR9814255A (pt) | 2000-10-10 |
| EP1037668A1 (en) | 2000-09-27 |
| AU1757799A (en) | 1999-06-28 |
| NO20002793D0 (no) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Engineering a second‐order DNA logic‐gated nanorobot to sense and release on live cell membranes for multiplexed diagnosis and synergistic therapy | |
| Zhang et al. | Smart and functionalized development of nucleic acid‐based hydrogels: Assembly strategies, recent advances, and challenges | |
| O’Hagan et al. | Photocleavable ortho-nitrobenzyl-protected DNA architectures and their applications | |
| Lu et al. | DNA assembly‐based stimuli‐responsive systems | |
| Shang et al. | Bioorthogonal disassembly of hierarchical DNAzyme nanogel for high-performance intracellular microRNA imaging | |
| Meng et al. | DNA amplifier-functionalized metal–organic frameworks for multiplexed detection and imaging of intracellular mRNA | |
| Hu et al. | DNA nanoflowers for multiplexed cellular imaging and traceable targeted drug delivery | |
| Czogalla et al. | DNA nanostructures on membranes as tools for synthetic biology | |
| He et al. | Self-assembly of DNA origami for nanofabrication, biosensing, drug delivery, and computational storage | |
| Khisamutdinov et al. | Fabrication of RNA 3D nanoprism for loading and protection of small RNAs and model drugs | |
| Jahanban-Esfahlan et al. | Static DNA nanostructures for cancer theranostics: Recent progress in design and applications | |
| ATE237312T1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
| Chakraborty et al. | Harnessing the physicochemical properties of DNA as a multifunctional biomaterial for biomedical and other applications | |
| WO2018082126A1 (zh) | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 | |
| EP1633784A4 (en) | OVR110 ANTIBODY COMPOSITIONS AND USE METHOD | |
| Wu et al. | DNA hydrogels and their derivatives in biomedical engineering applications | |
| ATE549401T1 (de) | Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität | |
| ATE187497T1 (de) | Neue konjugate zum einführen von nukleinsäure in höhere eukaryotische zellen | |
| BRPI0414222A (pt) | oligonucleotìdeos modificados por inibição da telomerase | |
| AR014054A1 (es) | Una particula para trasnfectar celulas eucariotas superiores con moleculas de acidos nucleicos in vitro e in vivo, un metodo para su preparacion, unacomposicion farmaceutica que contiene una cantidad farmaceuticamente efectiva de dicha particula y un kit de piezas destinado a la preparacion, la | |
| Huang et al. | Self-assembled DNA nanostructures-based nanocarriers enabled functional nucleic acids delivery | |
| Xiong et al. | DNA origami post‐processing by CRISPR‐Cas12a | |
| US20200405649A1 (en) | Dna origami nanoparticle delivery of programmed chromosome breakage machinery | |
| Liu et al. | Aptamer-incorporated hydrogels for visual detection, controlled drug release, and targeted cancer therapy | |
| Di et al. | Design, bioanalytical, and biomedical applications of aptamer-based hydrogels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |